Team

The best science requires both specialized expertise and interdisciplinary collaboration. To better achieve this important balance while improving cost efficiency, RS designed a totally new decentralized scientific staffing model: field-leading academic experts from around the world work together alongside industry veterans on hyper-specialized virtual R&D teams.

About the RS Internal Leadership Team

RS is led by a multi-disciplinary team of drug discovery, data science, and venture capital veterans who have founded, built, and led biotech companies worth billions. The internal RS leadership team plays three important roles: 1) They lead end-to-end drug discovery for all RS companies and their drug programs; 2) They assemble and manage large teams of external researchers and drug discovery specialists; and 3) They build and lead valuable research and technology platform capabilities designed to empower all RS companies.

Adam Kolom
Co-Founder and Partner, CEO
Adam Kolom
Co-Founder and Partner, CEO

Adam Kolom is a biotech entrepreneur and private equity investor. Adam co-founded and led two of the world’s largest cancer immunotherapy research initiatives and has overseen more than $850 million in biotechnology and healthcare investments. Prior to founding Related Sciences, Adam co-founded Sean Parker’s $250 million nonprofit, the Parker Institute for Cancer Immunotherapy, where he worked closely with Sean designing the Institute, assembling its network of centers, building its roster of scientific talent, and leading over 40 biopharma partnerships.  Before PICI, Adam was Managing Director of the Cancer Research Institute's venture capital fund and global clinical trials program, a member of the healthcare private equity team at General Atlantic, and a management consultant at McKinsey & Company. Adam graduated with honors from the Wharton School at UPenn with a degree in finance and economics.

Jack Milwid
Co-Founder and Partner, President
Jack Milwid
Co-Founder and Partner, President

Jack Milwid is a scientist, entrepreneur, and investor. As a founder of biotech companies worth billions, Jack has led R&D teams, invented platform technologies, and set strategy to create the next generation of life-saving medicines for patients. Prior to founding Related Sciences, Jack was a Principal at Flagship Pioneering, where he was a founder of the cell and gene therapy company Sana Biotechnology (SANA), a founder and leader of R&D for the targeted gene therapy company Cobalt Biomedicine, and the founding head of strategy for the microbiome therapeutics company Kaleido Biosciences. Before Flagship, Jack was an entrepreneur at Third Rock Ventures where he cofounded cancer neoantigen vaccine pioneer, Neon Therapeutics. Jack has a PhD in Health Sciences and Technology from Harvard and MIT.

Brian Albrecht
Partner, Head of Drug Discovery
Brian Albrecht
Partner, Head of Drug Discovery

Brian Albrecht is a 20-year seasoned drug discovery scientist who has led discovery efforts for a multitude of therapeutic programs and helped to launch biotech companies worth billions. Prior to his leadership role at Related Sciences, Brian was a principal at Third Rock Ventures where he was a key founding contributor to several biotech companies including multi-billion-dollar biotech, Relay Therapeutics, and led large drug discovery teams at multiple significant biopharma companies including Rheos Medicines, Constellation Pharmaceuticals, and Amgen. Brian holds a PhD in chemistry from Colorado State University.

Matt Goldstein
Partner, Head of Clinical Strategy
Matt Goldstein
Partner, Head of Clinical Strategy

Matt Goldstein is a physician-scientist and entrepreneur. He has founded companies, built R&D teams, and led strategy and execution of both pre-clinical research and clinical development. Prior to joining the partnership at Related Sciences, Matt was an entrepreneur at Third Rock Ventures where he spent a decade building and operating Third Rock portfolio companies. He was responsible for building and leading the Immunology program at Tango Therapeutics, the centerpiece of Tango’s strategic multi-billion-dollar partnership with Gilead Sciences, Inc. He also served as the development head for Tango’s lead program which entered the clinic in 1H 2022. Matt was a co-founder of Neon Therapeutics leading Translational Medicine and Early Development through completion of their first clinical study and initial public offering. He is a graduate of Swarthmore College and the MD/PhD program at Stanford University, where he pioneered novel cancer immunotherapies in the lab of Ron Levy, MD. He completed his clinical training in Internal Medicine at Harvard Medical School, Brigham & Women’s Hospital.

Eric Czech
Partner, Head of Data Science
Eric Czech
Partner, Head of Data Science

Eric is a veteran machine learning platform architect specializing in immuno-informatics and statistical genetics.  Prior to Related Sciences, he engineered data pipelines at Bridgewater, led the development of infrastructure and predictive analytics products at music and insurance companies, and published statistical methods for high-throughput single-cell as well as multiplexed immunological imaging assays at HammerLab.  He graduated with a BS degree in Computer Science and Applied Mathematics from Brown University.

Swathi Boppana
Research Analyst
Swathi Boppana
Research Analyst

Swathi is an analyst on the Related Sciences research team, based in India.  She has a bachelor’s degree in pharmacy, a master’s of business administration in health care services, and is a registered pharmacist.  She has previously held contract positions at Thomson Reuters as an associate research analyst, at Amazon as a pharma associate and subject matter expert, and most recently worked at Alliantgroup as a medical analyst.

Jess Elman
Translational Biology Lead
Jess Elman
Translational Biology Lead

Jess Elman is a cellular and molecular biologist with deep expertise in preclinical models and drug development. Prior to Related Sciences Jess was a Senior Scientist at Sana Biotechnology where she helped bring several immuno-oncology therapeutics from early concept to IND enabling studies. Jess completed her PhD in Cell, Molecular and Developmental Biology at Tufts University.

Penny Feng
Translational Biology Lead
Penny Feng
Translational Biology Lead

Penny is a cancer biologist with extensive background in small molecule drug discovery, pharmacology, and translation.  Prior to joining Related Sciences, Penny was a senior scientist at Tango Therapeutics. She led the biology efforts for a key drug discovery program from conception to IND-enabling stage. Prior to Tango Therapeutics, Penny was a presidential postdoctoral fellow at Novartis Institutes for BioMedical Research. Penny holds a DPhil from University of Oxford, having trained in the laboratory of Prof. Sir Peter Ratcliffe.

Dana Foss
Head of Therapeutic Technologies
Dana Foss
Head of Therapeutic Technologies

Dana Foss is a protein and RNA biochemist with extensive experience in genome editing, RNA silencing, and delivery of therapeutic macromolecules. Prior to Related Sciences Dana was a postdoctoral researcher at UC Berkeley supervised by Ross Wilson and Jennifer Doudna, where she engineered new methods of delivering CRISPR-Cas9 into human immune cells as a biological therapeutic.  Dana holds a PhD in Biochemistry from the University of Ottawa.

Daniela Grinis
Research Associate
Daniela Grinis
Research Associate

Daniela Grinis is a researcher focused on molecular biology and cloning.  Prior to RS, Daniela was a part of a CRISPR screening team working with bacterial and mammalian tissue culture to identify impactful enzymes for translation into therapeutic products, and a member of a microbiology lab that studied DNA repair and recombination mechanisms in E.coli using a range of molecular cloning techniques. Daniela graduated from the University of Massachusetts Amherst with a Bachelor of Science in Biology.

Jeff Hammerbacher
Co-Founder
Jeff Hammerbacher
Co-Founder

Jeff Hammerbacher is a scientist, software developer, entrepreneur, and investor. Jeff has founded and led teams that have produced dozens of scientific publications with hundreds of citations per year, 3 of the world's most popular open source database systems, over 100 angel investments, and a public company with a market capitalization of several billion dollars. Prior to founding Related Sciences, Jeff was the Principal Investigator of Hammer Lab, a founder and the Chief Scientist of Cloudera, an Entrepreneur-in-Residence at Accel, the manager of the Data team at Facebook, and a quant at Bear Stearns. In addition to his work at Related Sciences, Jeff is an angel investor with Techammer and is a board member at Ciox and Cytel. Jeff has a bachelor's degree in Mathematics from Harvard University.

Daniel Himmelstein
Head of Data Integration
Daniel Himmelstein
Head of Data Integration

Daniel Himmelstein is a leading data scientist focused on integrating large scale omics data, turning biological knowledge into machine-optimized networks and databases.  Prior to Related Sciences, Daniel created several projects to advance computational methods for biomedical knowledge including Hetionet and Manubot. Hetionet is an open-source network that combines data from 29 resources and millions of studies to capture the knowledge from decades of biomedical research. Manubot is a system for open writing on GitHub, allowing authors from around the world to collaborate in a transparent and automated manner. Daniel received his PhD in Biological & Medical Informatics from the University of California, San Francisco. As an undergraduate at Cornell University, he majored in Biometry & Statistics.

https://github.com/dhimmel

Morgan Languirand
Research Associate
Morgan Languirand
Research Associate

Morgan Languirand is a scientific researcher specializing in molecular biology. Prior to Related Sciences, Morgan was part of a molecular diagnostic team focused on analyzing post TMA-PCR tests for COVID-19. Morgan graduated from the University of New Hampshire with a Bachelor of Science in Biology.

Melinda Lyman-Wright
Operational HR (Danforth)
Melinda Lyman-Wright
Operational HR (Danforth)

Melinda is an HR specialist that supports related Sciences through Danforth consulting.

Mike Morrison
Head of Molecular Discovery
Mike Morrison
Head of Molecular Discovery

Mike Morrison is a 17-year veteran of the biotechnology industry focusing on small-molecule drug discovery.  As an enzymologist, he has extensive experience in high-throughput screening, hit identification, and characterization of enzyme inhibitors.  Prior to Related Sciences, Mike was the head of Lead Discovery at Rheos Medicines where he directed all aspects of biochemistry, biophysics, structural biology, and cell pharmacology.  Prior to Rheos, Mike held positions at Epizyme, Ambit Biosciences, and Amgen.   Mike graduated from Wesleyan University with a BA/MA and holds a PhD in biological chemistry from MIT.

Ilya Rahkovsky
Senior Data Scientist
Ilya Rahkovsky
Senior Data Scientist

Ilya Rahkovsky is an experienced Data Scientist specializing in emerging technology and scientometrics. He previously worked as a Data Scientist at the CSET where he led the development of the Science Map (https://sciencemap.cset.tech), technology forecasting, and studies of venture capital investment. Before that Ilya was working as a senior research economist at the Economics Research Service of USDA modeling demand and information use by consumers. Ilya has a Phd in Economics from the Michigan State University and taught Statistics and Machine Learning at the Johns Hopkins University.

Brett Treacy
Controller
Brett Treacy
Controller

Brett Treacy is a seasoned Financial Controller with broad-based accounting, finance, and analytical experience from senior roles in private equity, biotech, and public accounting firms. Prior to Related Sciences, Brett served as an external Controller for multiple startup biotech companies while working at Danforth Advisors.  Brett previously also served as the Associate Director of Finance for Accent Therapeutics, the Director of Financial Planning and Analysis at Mondo, the Controller at Equity Resource Investments, and an Accounting Manager at Prague & Company. In these roles, Brett has been instrumental in building out multiple companies’ financial organizations, ensuring accurate and timely reporting of metrics, and providing growth-enabling leadership. Brett is currently completing his Master of Science in Taxation from Northeastern University and graduated with a Bachelor of Applied Science in Finance from Oakland University.

Rafał Wojdyła
Head of Data Engineering
Rafał Wojdyła
Head of Data Engineering

Rafał Wojdyła specializes in data engineering.  Prior to Related Sciences Rafal worked at Spotify on data storage, processing and machine learning, and helped to build the largest processing cluster in Europe as well as a range of open and closed source libraries.  Rafal graduated from the AGH University of Science and Technology with a degree in Computer Science.

About the RS External Leadership and Model

RS brings together globally distributed field-leading experts from both academia and industry to work together on specialized R&D teams tailored to the unique needs of each drug program or research area. In contrast to a traditional biotech's Scientific Advisory Board, each RS "Biology/Clinical/Informatics Lead" plays a more active, significant, and engaging role in shaping RS science and drug discovery strategies.  Working on an ongoing basis alongside other eminent peers from complementary fields, each RS Lead acts like a "fractional CSO/CMO" to one or more drug discovery programs of high relevance to their broader academic interests, creating a productive new mode for top scientists to participate in industry R&D without having to leave academia.

Kevin Bi
Computational Biology Lead
Danger BIO
Kevin Bi
Computational Biology Lead

Kevin Bi is a computational biologist specializing in single cell profiling and immuno-informatics. He is a staff scientist in the Department of Medical Oncology at the Dana-Farber Cancer Institute, where his work focuses on identifying immune evasion mechanisms in the microenvironment of renal cell carcinoma. He has also worked in preclinical models to characterize subsets of exhausted T cells mediating the response to checkpoint blockade immunotherapy. Kevin graduated from Columbia University with a Bachelor of the Arts in Biochemistry.

Clare Bryant
Scientific Founder and Biology Lead
Danger BIO
Clare Bryant
Scientific Founder and Biology Lead

Clare Bryan is Professor of Innate Immunity at the University of Cambridge in the UK. Clare uses multi-disciplinary approaches to study how Pattern Recognition Receptors signal in response to infectious and non-infectious stimuli.  She is internationally recognized for her cutting-edge research to understand the mechanisms of formation, and the composition of, the large signaling complexes triggered by Pattern Recognition Receptor activation.  This research focusses on understanding the fundamental mechanisms by which Toll-like receptors and inflammasomes signal to integrate inflammatory processes with a view to developing new treatments for infectious and inflammatory diseases.  She has published extensively, is a highly cited scientist, has served on editorial boards (including the Journal of Immunology, The Journal of Biological Chemistry and EMBO) and is a Fellow of the British Pharmacology Society. She has broad interactions with industry including spending time on sabbatical at Genentech and GSK, serving on Biotech scientific advisory boards, consultancy work with pharma and translating her own research in a drug discovery project with Apollo Therapeutics.

Jill Buyon
Clinical Lead
Danger BIO
Jill Buyon
Clinical Lead

Dr. Jill Buyon is the Sir Deryck and Lady Va Maughan Professor of Rheumatology, Director of the Division of Rheumatology at New York University Grossman School of Medicine, and Director of the NYU Lupus Center.  She is a researcher and clinician specializing in the treatment of systemic lupus erythematosus, neonatal lupus, and rheumatic diseases in pregnancy. Dr. Buyon has received the Distinguished Clinical Investigator Award as well as Master distinction from the American College of Rheumatology, the Evelyn V Hess Lifetime Achievement Award for Research in Lupus from the Lupus Foundation of America, and the Halsted R. Holman Award for Excellence in Clinical Research. She is an active member of the Association of American Physicians. She has had continuous NIH funding for over two decades.

Dr. Buyon led the first multicenter study in SLE which resulted in a paradigm change with regard to the safety of exogenous estrogens in women of reproductive age and those postmenopausal. The SLE activity index SELENA-SLEDAI and the flare index were both generated as part of this study and are instruments widely used in current FDA registrational trials.  She led the “Preventive Approach to Congenital Heart Block with Hydroxychloroquine (PATCH)” trial and held a MERIT grant on the pathogenesis of anti-Ro associated congenital heart block. She has initiated an NIH-funded study, “Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ),” which is a multi-site clinical trial evaluating the efficacy of home fetal heart rate and rhythm monitoring. She continues to operate the national Research Registry for Neonatal Lupus, which she founded in 1994 and which has generated the bulk of evidence-based information on this disease. She was an mPI for a grant through the Accelerating Medicines Partnership (AMP) titled “Multi-Ethnic Translational Research Optimization (METRO) Lupus Consortium,” and now serves as the lead of the Lupus disease team in program’s second iteration, AMP AIM (AMP Autoimmune and Immune Mediated Diseases) on a grant titled “Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT).” She  directs the COMPEL (“Translational Center of Molecular Profiling in Preclinical and Established Lupus”) P50.


Yanick Crow
Scientific Founder and Biology + Clinical Lead
Danger BIO
Yanick Crow
Scientific Founder and Biology + Clinical Lead

Yanick Crow is a clinician-scientist and Fellow of the Academy of Medical Sciences. He is a practicing Clinical Geneticist, and has developed a research interest in monogenic disorders associated with an up-regulation of type I interferons - a set of inborn errors of immunity resulting from abnormal sensing, inappropriate stimulation, or defective negative regulation of the type I interferon system. Understanding of these so-called type I interferonopathies has the potential to provide insights into immunological homeostasis, mechanisms of self / non-self discrimination and viral immunity. Importantly, this work is also leading to novel therapeutic strategies aimed at treating this devastating group of diseases.

Peter Du
Computational Biology Lead
Danger BIO
Peter Du
Computational Biology Lead

Peter Du is a computational biologist working on uncovering mechanisms of cancer immune escape using statistical and machine learning methods. Previously, he worked at the Broad Institute to discover immune resistance mechanisms using high throughput functional genomics. Peter received his undergraduate degree from Princeton University in Molecular Biology with a certificate in Neuroscience and is currently a graduate student at Stanford University.

Kate Fitzgerald
Scientific Founder and Biology Lead
Danger BIO
Kate Fitzgerald
Scientific Founder and Biology Lead

Dr. Fitzgerald is Professor of Medicine, Director of the Program in Innate Immunity, and the Worcester Foundation in Biomedical Sciences Chair at the University of Massachusetts Chan Medical School. Her work is focused on the innate immune system aimed at understanding the molecular basis of the inflammatory response in both normal responses (eg. Infection) and disease. The long-term goal of her work is to determine how innate immune sensing and signaling contribute to infectious, inflammatory, and autoimmune diseases in humans.

Dr. Fitzgerald completed all of her education in Ireland. She received her B.Sc. in Biochemistry in 1995 from University College Cork, Ireland and her PhD in Biochemistry in 1999 from Trinity College Dublin, Ireland. After pursing a post-doctoral fellowship at Trinity College Dublin, she joined UMass Chan as Instructor and is currently a tenured Professor.

Dr. Fitzgerald is an elected fellow of the American Society of Microbiology and was recently elected to the Royal Irish Academy, the National Academy of Sciences and the National Academy of Medicine. She has also received several awards including the  Thermo-Fischer Meritorious Career Award (from the American Association of Immunology), the Saint Patrick’s Day Medal (from the Irish Government and Science Foundation Ireland), the Milstein Award for Excellence in Interferon and Cytokine research (from the International Cytokine and Interferon Society), amongst others.

She has extensive service both locally at UMass Chan and nationally including service on local and national advisory boards (e.g., Massachusetts Center For Pathogen Readiness, NIAID Board of Scientific Councillors, Burroughs Wellcome Fund Pathogenesis of Infectious Diseases and the Cancer Research Institute). She was also the recent past President of the International Cytokine and Interferon Society.

Nir Hacohen
Scientific Founder and Biology Lead
Danger BIO
Nir Hacohen
Scientific Founder and Biology Lead

Dr. Nir Hacohen is the Director of the Center for Cancer Immunology at Massachusetts General Hospital, and the David P. Ryan Professor of Medicine at Harvard Medical School. He is the Director of the Center for Cell Circuits at the Broad Institute of MIT and Harvard. Dr. Hacohen is a recipient of the NIH Director’s Innovator award, the MGH Scholars Award and the Martin Prize. He completed his Ph.D. at the Stanford Biochemistry Department, and was a fellow at the Whitehead Institute at MIT.  Dr. Hacohen developed an international workshop for advancing the careers of young cancer immunologists. He also founded Neon Therapeutics, which is now part of BioNTech.

Dr. Hacohen has pioneered systems biology tools that generate comprehensive cellular and molecular models of immunological processes and enable personalized immunotherapies. In the area of cell-level systems biology, he carried out genome-wide genetic screens in primary immune cells and identified genetic variants, transcription factors, chromatin regulators, signaling proteins, RNA and protein synthesis-degradation mechanisms and splicing factors driving the sensing of pathogens by myeloid cells. In the area of cell type discovery, he contributed to the human cell atlas by discovering new immune cell types, including human dendritic cell subsets and their progenitors as well as T cells and their differentiation states. He also identified cell states associated with disease in bacterial/viral sepsis, lupus nephritis and cancer immunity, and discovered spatially-organized immune cell structures in tumors. In the area of cancer vaccines, he created machine-learning based methods to predict cancer antigens, and developed the first personalized approach to immunotherapy using vaccines that target patient-specific tumor neoantigens. This led to clinical trials in melanoma and glioblastoma multiforme, demonstrating induction of tumor-specific T cells that kill malignant cells and that are durable for many years. His lab is currently working on using systems-level technologies to understand mechanisms of human immune diseases and model them in mice, with the goal of catalyzing new therapeutic strategies.

Jeff Ishizuka
Scientific Founder and Biology + Clinical Lead
Danger BIO
Jeff Ishizuka
Scientific Founder and Biology + Clinical Lead

Dr. Ishizuka is Assistant Professor of Medicine, Immunobiology and Pathology at Yale School of Medicine. He is the principal investigator of a basic and translational immuno-oncology laboratory and a practicing medical oncologist at Yale Cancer Center. He completed his D.Phil. in Immunology at Oxford University and the National Institutes of Health on a Rhodes Scholarship. He subsequently pursued his medical doctorate at Harvard Medical School and the Massachusetts Institute of Technology, internal medicine residency at Brigham and Women’s Hospital and a fellowship in medical oncology at the Dana-Farber Cancer Institute. His laboratory focuses on defining and targeting mechanisms of tumor inflammation to improve immunotherapy with a particular focus on triggering dsRNA sensing pathways, the use of functional genomics to identify novel therapeutic targets and the development of new human translational approaches. He has helped to initiate and develop or served as scientific advisor to several oncology and immuno-oncology companies including Jounce Therapeutics, Kronos Bio and Tango Therapeutics.

Jonathan Kay
Scientific Founder and Clinical Lead
Danger BIO
Jonathan Kay
Scientific Founder and Clinical Lead

Jonathan Kay, MD, is Professor of Medicine and Population and Quantitative Health Sciences and holds the Timothy S. and Elaine L. Peterson Chair in Rheumatology at the UMass Chan Medical School in Worcester, where he directs Clinical Research in the Division of Rheumatology and is Associate Director of the Medical Scientist Training Program (MSTP)-funded MD/PhD Program. His clinical appointment is as a Physician at UMass Memorial Medical Center, also in Worcester. He received his medical degree from the University of California School of Medicine in San Francisco, California. He then completed an internship and residency at the Hospital of the University of Pennsylvania in Philadelphia and fellowships in rheumatology and immunology at the Brigham and Women’s Hospital and Harvard Medical School in Boston, Massachusetts.

Dr. Kay is a Fellow of the American College of Rheumatology and of the American College of Physicians.  In 2018, he received the Distinguished Service Award from the American College of Rheumatology and he was awarded honorary membership in EULAR.  He is an ad hoc reviewer for many journals and a member of the editorial board of RMD Open.

Dr. Kay’s clinical interests span the spectrum of rheumatic diseases, with special interest in rheumatoid arthritis, spondyloarthropathies, and other forms of inflammatory arthritis.  He was a member of the group that developed the 2010 ACR/EULAR Diagnostic and Classification Criteria for Rheumatoid Arthritis.  He chaired the Rheumatology Working Group and was a member of the Internal Medicine and Musculoskeletal Topic Advisory Groups for the World Health Organization in its Revision of the International Classification of Diseases (ICD)-11.

Over the past three decades, his clinical research has focused on nephrogenic systemic fibrosis (formerly known as nephrogenic fibrosing dermopathy), β2-microglobulin amyloidosis, and other rheumatologic problems of patients with chronic kidney disease.  He has been a principal investigator on over 60 clinical trials of novel therapies for rheumatoid arthritis, axial spondyloarthritis, systemic lupus erythematosus, gout, and osteoarthritis.  Over the past decade, he has been involved in the development of biosimilars to treat rheumatic diseases.  Dr. Kay lectures internationally and is the author of more than 260 publications and book chapters.




Andy Minn
Scientific Founder and Biology + Clinical Lead
Danger BIO
Andy Minn
Scientific Founder and Biology + Clinical Lead

Dr. Andy Minn is a Professor in the Department of Radiation Oncology and an Investigator in the Abramson Family Cancer Research Institute at the University of Pennsylvania. He is also Director of the Mark Foundation Center for Immunotherapy, Immune Signaling, and Radiation, and a project member in the Parker Institute for Cancer Immunotherapy. He received his MD and PhD from the University of Chicago and finished his residency in radiation oncology along with his post-doctoral training at Memorial Sloan-Kettering Cancer Center. His research seeks to understand key mechanisms of cancer immunotherapy resistance. Specifically, his work focuses on the role of pattern recognition receptors and interferon signaling pathways, which are pathways that are typically activated when normal cells become infected with a virus. Surprisingly, cancers and many cancer therapies also can activate these pathways, prompting an interest in understanding how this happens, the impact on anti-tumor immunity, and its clinical significance. An overarching goal is to translate this understanding to better inform the design of clinical trials. Dr. Minn’s work has been published in prestigious scientific journals such as Cell, Immunity, and Nature. He is also a member of the American Society for Clinical Investigators (ASCI).

Yorgo Modis
Scientific Founder and Biology Lead
Danger BIO
Yorgo Modis
Scientific Founder and Biology Lead

Yorgo Modis is Professor of Virology and Immunology at the University of Cambridge in the UK.

Yorgo’s research focuses on understanding the fundamental mechanisms of enveloped RNA virus assembly, cell entry, and innate immune recognition. By integrating macromolecular structure determination with multiscale imaging and functional assays, his work has uncovered the molecular mechanisms underlying key steps of infection and antiviral immune responses.

Yorgo’s early work established how class II envelope glycoproteins, found in many virus families including important human pathogens, drive fusion of the viral and cellular membranes, a crucial cell-entry step. His widely cited studies on flavivirus membrane attachment and fusion (PNAS:2003; Nature:2004a; J.Virol:2005, J.Virol:2006) have become textbook knowledge (Fields Virology) and sparked much new research. He also contributed to the first structure determination of a protein translocation channel (Nature:2004b).

More recently, Yorgo discovered how RNA delivered into cells by enveloped RNA viruses including SARS-CoV-2 is recognized and distinguished from cellular RNAs with the necessary sensitivity and specificity by a molecular proofreading mechanism by the innate immune sensor MDA5 (Mol.Cell:2018; EMBO J.:2012; PNAS:2012). He showed how genetic variants can cause MDA5 to misrecognize endogenous RNA as viral RNA to cause autoinflammatory disease (Nat.Commun.:2021).

In parallel, Yorgo has shown how structural and chromatin-modifying properties of the transcriptional repressor complexes HUSH and KAP1 provide a newly recognized type of innate immune response by epigenetically regulating the expression of viral genes and endogenized sequences in human chromatin (Nucleic Acids Research:2020; Nat.Commun.:2020; PNAS:2019; Nat.Commun.:2018; Nat.Genet.:2017).




John Monroe
Biology Lead
Danger BIO
John Monroe
Biology Lead

John Monroe, PhD is an Emeritus Professor at the Perelman School of Medicine at the University of Pennsylvania. Most recently he led Genentech’s Immunology Discovery Department, and was responsible for new target discovery and pre-clinical validation. He also headed the Genentech Immunology Precision Medicine Department and determined precision medicine strategies and early clinical validation of biomarkers for patient selection. He was a tenured Professor at the University of Pennsylvania School of Medicine where for over 20 years he oversaw a research lab and published seminal papers in the field of B lymphocyte biology and immune cell tolerance.
 
Dr. Monroe received his Ph.D. in Immunology from Duke University studying immune cell receptor signaling and did a post-doctoral fellowship at Harvard Medical School studying T cell modulation of immune responses.  He is a former Vice Chair for Research in the Department of Pathology at UPENN and directed their Cancer Immunology Program. He has served on many review committees and editorial boards including as Deputy Editor for Immunological Reviews.

Arpit Panda
Computational Biology Lead
Danger BIO
Arpit Panda
Computational Biology Lead

Arpit Panda is a systems immunologist, data scientist and a physician-scientist in-training. In a previous life, Arpit developed a range of software development skills while working as a full-stack engineer and serving on the founding team at a Southern California amateur sports streaming startup. After becoming excited by the crucial and complex problems that remain unsolved in health and medicine, he switched fields and began studying the mechanisms of response and resistance to immunotherapy in Nick Haining's lab at Harvard. He was involved in validating Adar1 as a potential immunotherapy target and continues studying the role of RNA modifiers in tumor immunology. Before Related Sciences, Arpit helped establish the bioinformatics team and led early preclinical bioinformatic drug discovery efforts for neuromuscular diseases at 4:49 NewCo, a 5 AM Ventures company. Arpit obtained his B.S. from the California Institute of Technology, and his Masters in Immunology from Harvard . He's currently an MD PhD candidate at the University of Chicago.

Boris Reizis
Scientific Founder and Biology Lead
Danger BIO
Boris Reizis
Scientific Founder and Biology Lead

Boris Reizis is Professor of Pathology and Samuel A. Brown Professor of Medicine, Director of the Translational Immunology Center and Interim Director of the Colton Center for Autoimmunity at NYU Grossman School of Medicine. His lab is credited for studies of dendritic cell development and function, as well as on the pathogenesis of systemic autoimmunity in humans and animal models. His work has been recognized with the Dr. William E. Paul Distinguished Innovator Award from the Lupus Research Alliance and Fredrick W. Alt Award for New Discoveries in Immunology from the Cancer Research Institute.

Stefani Spranger
Scientific Founder and Biology Lead
Danger BIO
Stefani Spranger
Scientific Founder and Biology Lead

Dr. Spranger pursued her scientific training at Ludwig-Maximillians-Universität (LMU) in Munich, Germany, first as an undergraduate in biology and then completing a Ph.D. in immunology. She then joined the University of Chicago as a postdoctoral fellow, supported by the German Research Foundation as well as the Cancer Research Institute, later moving to her current position as assistant professor at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. She has been awarded the Howard S. and Linda B. Stern Career Development Professorship and is a Pew-Stewart Scholar. Her work seeks to elucidate the mechanisms and pathways underlying the interaction between the immune system and cancer using mouse models that recapitulate the co-evolution of tumor progression and the anti-tumor immune response. One major emphasis of her work is on dendritic cell and T cell interactions both during T cell activation in the lymph node but also in the tumor microenvironment.

E. William St. Clair
Clinical Lead
Danger BIO
E. William St. Clair
Clinical Lead

Eugene William (Bill) St. Clair is the W. Lester Brooks, Jr. Distinguished Professor of Medicine, Chief of the Division of Rheumatology and Immunology, and Professor in Immunology at the Duke University School of Medicine.  Dr. St. Clair's research focus is on the pathogenesis and treatment of rheumatoid arthritis (RA). 

Dan Stetson
Scientific Founder and Biology Lead
Danger BIO
Dan Stetson
Scientific Founder and Biology Lead

Dr. Stetson is a Professor of Immunology at the University of Washington.  Dr. Stetson’s work has been recognized with a Rita Allen Scholar Award, a Burroughs Wellcome Investigator Award, a Howard Hughes Medical Institute Faculty Scholar Award, and a NIH Directors Award for Transformative Research.  Dan studies intracellular nucleic acid detection and antiviral responses. His lab has identified pathways, sensors, and key regulators of the antiviral response. In particular, his work has demonstrated that specific human immune diseases are caused by excessive activation of the same antiviral responses that protect us from infection.

Paul Thompson
Scientific Founder and Biology Lead
Danger BIO
Paul Thompson
Scientific Founder and Biology Lead

Paul Thompson is the Director of Program in Chemical Biology at the University of Massachusetts Medical School.  He is also a Professor in the Department of Biochemistry and Molecular Biotechnology.  His research focuses on the development of novel therapeutics for a range of diseases including cancer, rheumatoid arthritis, inflammatory bowel disease, and lupus.  In particular, he is a world leader in the biology and biochemistry of the Protein Arginine Deiminases.  Based on his research in this area, Paul founded Padlock Therapeutics which focused on identifying therapeutics for a range of inflammatory diseases.  This company was acquired in 2016 for up to $600M.  

Paul received his BSc and PhD degrees from McMaster University in Canada before moving to the United States to take a postdoctoral position with Dr. Philip Cole at the Johns Hopkins School of Medicine.  Paul then moved to the University of South Carolina to begin his independent career before moving to the Department of Chemistry at The Scripps Research Institute, Scripps Florida, in May 2010.  Paul subsequently moved to the University of Massachusetts Medical School in Aug 2014.  Paul has published more than 180 articles in major scientific journals including Nature, Cell, Nature Structural and Molecular Biology, and the Journal of the American Chemical Society.  Paul has also won a number of awards including a Canadian Institutes of Health Research Postdoctoral Fellowship and a Camille Dreyfus Teacher-Scholar Award.  He is also a Fellow of the Royal Society of Chemistry.

John Wherry
Scientific Founder and Biology Lead
Danger BIO
John Wherry
Scientific Founder and Biology Lead

Dr. E. John Wherry is the Barbara and Richard Schiffrin President’s Distinguished Professor, Chair of the Department of Systems Pharmacology and Translational Therapeutics in the Perelman School of Medicine and Director of the UPenn Institute for Immunology.  Dr. Wherry received his Ph.D. at Thomas Jefferson University in 2000 and performed postdoctoral research at Emory University from 2000-2004. Dr. Wherry has received numerous honors including the Distinguished Alumni award from the Thomas Jefferson University, the Cancer Research Institute’s Frederick W. Alt Award for New Discoveries in Immunology, the Stanley N. Cohen Biomedical Research Award from the University of Pennsylvania Perelman School of Medicine and was inducted as an AAAS Fellow in 2021.  As of November 2021, Dr. Wherry has over 275 publications, an H-Index of 117, and his publications have been cited over 70,000 times.

Dr. Wherry helped pioneered the field of T cell exhaustion, the mechanisms by which T cell responses are attenuated during chronic infections and cancer. He helped identify the role of the “checkpoint” molecule PD-1 and others for reinvigoration of exhausted T cells in cancer. Dr. Wherry’s work has defined the underlying molecular and epigenetic mechanisms of exhausted T cells. His laboratory has also recently focused on applying systems immunology approaches to define Immune Health patients across a spectrum of diseases. In 2020-2021, Dr. Wherry’s laboratory focused considerable efforts on the immunology of COVID-19 and SARS-CoV-2 vaccination including establishing a new Immune Health Project to interrogate and use immune features to identify novel treatment opportunities.

Jimmie (Chun) Ye
Scientific Founder and Biology Lead
Danger BIO
Jimmie (Chun) Ye
Scientific Founder and Biology Lead

Jimmie Ye is an Associate Professor of Medicine, at UCSF who specializes in human genomics, single-cell genomics, computational biology, and immunology.  Jimmie has a track record of developing and applying innovative experimental and computational genomic approaches to study the molecular basis of immune-mediated disease and natural human immune variation.  Jimmie serves as a biology lead for Related Sciences and ImmunoAI, consults for Maze Therapeutics, and is a founder of Survey Genomics.

As a postdoc, he led the ImmVar Consortium to map the genetic determinants of immune response in more than 500 healthy humans across three ethnicities, discovering that disease-associated variants often differentially modulated gene expression across cell types and stimuli, suggesting the importance of the interaction between genetics and cellular context in the development of disease. The Ye lab expands on the molecular profiling work of ImmVar  to include bulk and single-cell transcriptomic, epigenomic, and proteomic sequencing to enable the mapping of variants associated with chromatin accessibility total transcript abundance and isoform structure. In 2018, the Ye Lab developed an algorithm that enables population scale single-cell sequencing by leveraging natural genetic variation encoded in single cell sequencing libraries and applied the approach to sequence > 10M immune cells from patients with autoimmunity, infectious disease including COVID19, cancer, and healthy controls, generating the largest reference of immune cell profiles in humans. Currently, the Ye Lab focuses on building new tools to encode spatial, temporal, and cellular activation information in single cell libraries and further scale single cell sequencing by 10-fold.